16.89MMarket Cap-452P/E (TTM)
0.431High0.409Low161.10KVolume0.409Open0.410Pre Close67.86KTurnover0.48%Turnover RatioLossP/E (Static)40.13MShares2.95052wk High0.73P/B14.28MFloat Cap0.39752wk Low--Dividend TTM33.94MShs Float13.800Historical High--Div YieldTTM5.24%Amplitude0.397Historical Low0.421Avg Price1Lot Size
Cognition Therapeutics Stock Forum
Alzheimer’s disease, a progressive neurodegenerative disorder, remains one of the most challenging areas of study in medical research. The pursuit of effective treatments has led to numerous studies and trials aimed at understanding and mitigating the effects of this disease. Recently, Cognit...
Cognition Therapeutics Publishes Eeg Findings From Phase 2 Sequel Study of Ct1812 in Mild-to-Moderate Alzheimer’s Disease
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
Cognition Therapeutics (NASDAQ: CGTX) has published results from the SEQUEL study of CT1812, their lead candidate for Alzheimer's disease treatment, in The Journal of Prevention of Alzheimer's Disease.
The single-site study measured brain wave patterns in 16 adults with mild-to-moderate Alzheimer's after 29 days of treatment. CT1812-trea...
Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company focused on developing treatments for neurodegenerative disorders, has announced promising results from their proof-of-concept Phase 2 SHINE trial. This study evaluated the efficacy of CT1812, an oral medication, in patients with mild-to-moderate Alzh...
No comment yet